Heparin is used to prevent or treat conditions of the blood vessels, heart, and lungs. It is also used in blood transfusion, blood sampling during prophylaxis treatment, and treating blood clotting disorders. Heparin Market may be used to diagnose and treat disseminated intravascular coagulation, a serious blood condition. Heparin is sometimes used alone or in combination with aspirin to prevent miscarriage and other complications.
Heparin Market, also known as
unfractionated heparin (UFH), is a glycosaminoglycan that occurs naturally. In
medicine, it is used as an anticoagulant. It is especially useful in the
treatment of heart attacks and unstable angina. It is injected into a vein or
under the skin. It is used to treat a variety of medical conditions, including
acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial
fibrillation, as well as cardiopulmonary bypass and hemofiltration during
cardiac surgery. It is also used in the administration of major orthopedic
procedures such as hip and knee replacements.
The rising prevalence of venous thrombosis and cardiovascular diseases is driving the global heparin market. Furthermore, the use of the Heparin Market in various surgeries, such as orthopedic and heart surgeries, as well as an increase in the number of patients undergoing such procedures, contribute to the growth of the heparin market. Furthermore, the availability of synthetic and semi-synthetic heparin mimetics that aid in the treatment of cancer, coagulation, and inflammatory diseases is expected to provide lucrative opportunities for heparin adoption. Furthermore, increased government support for healthcare infrastructure improvements and comprehensive R&D activities to develop heparin with enhanced therapeutic potential and minimal side effects drive the heparin market's growth.Key Players
Anselm Pharmaceuticals,
Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr.
Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO
Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical
Industries Ltd., and United Biotech (P) Ltd are key players
Comments
Post a Comment